GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
NEUROGESX INC. (NGSX) [hlAlert]

Rating:
Buy NGSX
down 99.88 %

NEUROGESX INC. (NGSX) rated Buy with price target $7 by Roth Capital

Posted on: Monday,  Dec 22, 2008  8:25 AM ET by Roth Capital

Roth Capital rated Buy NEUROGESX INC. (OTCBB: NGSX) on 12/22/2008. Previously Roth Capital rated Buy NEUROGESX INC. (OTCBB: NGSX) on 02/14/2008.,
when the stock price was $5.80. Since then, NEUROGESX INC. has lost 99.89% as of 08/27/2015's recent price of $0.01.
If you would have followed the previous Roth Capital's recommendation on NGSX, you would have lost 99.88% of your investment in 2751 days.

NeurogesX, Inc. (NeurogesX) is a biopharmaceutical company focused on developing and commercializing pain management therapies. The Company is assembling a portfolio of pain management product candidates and is developing new therapies based on known chemical entities. Its initial focus is on the management of chronic peripheral neuropathic pain conditions. The Company?s most advanced product candidate, Qutenza, a dermal patch containing a high concentration of synthetic capsaicin, is designed to manage pain associated with peripheral neuropathic pain conditions. The Company submitted to the United States Food and Drug Administration?s (FDA) an new drug application (NDA) for Qutenza for the management of pain associated with postherpetic neuralgia (PHN), in October 2008 which was filed by the FDA in December 2008. The Company's Products include Qutenza, NGX-1998, Acetaminophen Prodrugs (NGX-1576, NGX-9674, NGX-5752) and Opioid Prodrugs (NGX-6052).

ROTH researches emerging growth equities in the media, technology, telecommunications, healthcare, consumer, energy and industrial sectors. The research is focused on companies with market capitalization of between $100 million - $1 billion. Our coverage universe includes approximately 180 small cap growth companies around the globe including several companies from China. With an average market cap of approximately $500 million, our objective is to identify rapidly growing companies with significant long term growth prospects.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
12/22/2008 8:25 AM Buy
None
1.31 7.00
as of 12/24/2008
1 Week up  6.55 %
1 Month down  -26.34 %
3 Months up  116.66 %
1 YTD up  122.22 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
2/28/2008 9:25 AM Buy
None
4.20 9.00
2/14/2008 8:25 AM Buy
None
5.80 11.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy